FDA approves Avastin for platinum-resistant, recurrent ovarian cancer
the ONA take:
Roche has announced that the U.S. Food and Drug Administration (FDA) has approved Avastin (bevacizumab) for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with pacltiaxel, pegylated liposomal doxorubicin, or topotecan.
The drug is indicated for patients who have received no more than 2 prior chemotherapy regimens. The recommended dose of this indication is bevacizumab 10mg/kg every 2 weeks in combination with one of the above intravenous chemotherapy regimens, or bevacizumab 15mg/kg every 3 weeks in combination with topotecan.
The approval by the FDA is based upon the randomized, open-label, multicenter, phase 3 AURELIA trial, which investigated bevacizumab plus chemotherapy versus chemotherapy alone in 361 patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer that recurred within 6 months from the most recent treatment with platinum-based therapy.
Patients had a median age of 61 years. Median progression-free survival was 6.8 months and 3.4 months for chemotherapy plus bevacizumab and chemotherapy alone, respectively (P < 0.0001). Overall survival was 16.6 months and 13.3 months for chemotherapy plus bevacizumab and chemotherapy alone. This FDA approval is the sixth indication for Avastin.
Avastin (bevacizumab) approved for treatment of platinum-resistant recurrent epithelial ovarian cancer.
Cancer drug Avastin is already enjoying wide acceptance in Europe after it was approved for use earlier in the year. The same could happen in the United States soon as the Food and Drug Administration recently approved the use of Avastin as a treatment option alongside chemotherapy in battling platinum-resistant, recurrent ovarian cancer. Roche announced the approval Monday, based on results from a Phase III AURELIA study showing that using Avastin in combination with chemotherapy cut risks of worsening or death by up to 62 percent in women who have platinum-resistant, recurrent ovarian cancer compared to those who underwent chemotherapy alone.
"Avastin plus chemotherapy is the first new treatment option for women with this difficult-to-treat type of ovarian cancer in more than 15 years," said Roche Global Product Development Head and chief medical officer, Sandra Horning, M.D.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- High Symptom Burden With Polycythemia Vera Linked to QoL Impairment
- Bioimpedence Spectroscopy Improves Early Detection of Breast Cancer-Related Lymphedema in At-Risk Patients
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- MRD Negativity Associated With Prolonged Survival in Myeloma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Patient Navigation Reduces Delays in Diagnostic Resolution
- Fee-for-service Medicare Plans Linked to Improved Care During Last Year of Life
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|